Abbott Labs Raises 2026 Outlook After Q2 Earnings Beat
Abbott Laboratories (ABT) reported second-quarter 2026 results that exceeded analyst expectations, sending shares up about 2.5% in premarket trading. The company also raised its full-year earnings guidance.
Key Numbers
Abbott Laboratories (NYSE:ABT) delivered stronger-than-expected second-quarter results for 2026 and increased its full-year earnings guidance, sending its shares about 2.5% higher in premarket trading.
Key Financial Results
| Metric | Q2 2026 | Consensus |
|---|---|---|
| Revenue | Not disclosed | Beat |
| EPS | Not disclosed | Beat |
Year-over-year comparisons were not provided in the initial release.
Highlights from the Statement
The company stated that Q2 results were driven by strong performance in its diagnostics and medical devices segments. Specific figures were not disclosed in the preliminary announcement.
Guidance
Abbott raised its full-year 2026 earnings outlook, signaling management confidence in sustained momentum.
Stock Impact
ABT shares rose approximately 2.5% in premarket trading, reflecting investor optimism over the earnings beat and guidance raise.
What This Means for Investors
The guidance raise indicates improved operational performance, but investors await full details to assess growth sustainability.
Frequently Asked Questions
Found this useful? Share it